trial

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

NCTId NCT00308360
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 46
Sponsored by Nathan Kline Institute for Psychiatric Research
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
46
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
1999-09
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator
Research Foundation for Mental Hygiene, Inc.Collaborator

Investigators

2
Leslie L Citrome, MD, MPHPrincipal Investigator
Jan Volavka, MD, PhDPrincipal Investigator

Sites

1 total
Orangeburg, United States

Facts & assertions

3 sourced
Enrollment
46
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
Research Foundation for Mental Hygiene, Inc.
company
indication
Impulsive Behavior
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Leslie L Citrome, MD, MPH
person
Jan Volavka, MD, PhD
person